Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

atazanavir; boosted protease inhibitors; darunavir; hepatitis C virus; hepatotoxicity; liver toxicity; lopinavir; ritonavir; transaminases elevation; Adult; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Hepatitis B; Hepatitis C; Humans; Italy; Liver; Male; Middle Aged; Protease Inhibitors; Risk Factors; Ritonavir; Infectious Diseases; Pharmacology (medical); Medicine (all)